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Abstract: Recombinant viruses are novel therapeutic agents that can be utilized for treatment of
various diseases, including cancers. Recombinant viruses can be engineered to express foreign
transgenes and have a broad tropism allowing gene expression in a wide range of host cells. They can
be selected or designed for specific therapeutic goals; for example, recombinant viruses could be
used to stimulate host immune response against tumor-specific antigens and therefore overcome
the ability of the tumor to evade the host’s immune surveillance. Alternatively, recombinant viruses
could express immunomodulatory genes which stimulate an anti-cancer immune response. Oncolytic
viruses can replicate specifically in tumor cells and induce toxic effects leading to cell lysis and
apoptosis. However, each of these approaches face certain difficulties that must be resolved to achieve
maximum therapeutic efficacy. In this review we discuss actively developing approaches for cancer
therapy based on recombinant viruses, problems that need to be overcome, and possible prospects
for further development of recombinant virus based therapy.
Keywords: recombinant viruses; virus-based vaccines; oncolytic viruses; gene therapy; cell therapy;
chimeric antigen receptor (CAR) T-cell therapy
1. Introduction
Cancers are the second most common cause of death worldwide. According to statistical data,
the number of new cases increases every year despite significant improvements in existing therapy and
the emergence of new innovative therapeutic approaches [1]. Surgery, chemotherapy, and irradiation
are the mainstream therapeutic approaches used for cancer treatment; hormone and monoclonal
antibody therapy are also actively used [2].
Recently, gene and cell therapies were introduced as having significant potential for cancer
treatment. Gene therapy implies correction or modulation of the expression of a gene of interest in the
host. It can be used to achieve both increased expression of immunomodulating or oncosuppressor
genes as well as to inhibit oncogene expression leading to tumor regression [3]. Cell-mediated therapy
uses autologous patient cells, such as T lymphocytes and dendritic cells (DC), to induce an immune
response, or the use of tumor cells directly as tumor-specific antigen donors [4–6]. Due to natural
tropism toward tumor sites, the therapeutic potential of mesenchymal stem cells (MSCs) as vectors for
chemotherapeutic drug delivery is under extensive investigation [7]. Genetic modification of MSCs
has also been investigated, enabling the delivery of genes with oncosuppressive, immunomodulory or
pro-apoptotic properties [8]. However, cell-based therapy has a number of potential disadvantages,
mediated by the properties of cells. For example, T-cells can induce cytokine release syndrome because
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of uncontrolled release of cytokines [9]. Use of MSCs, in turn, has a risk of unlimited cell growth,
undesirable transformation and potential tumor formation [10].
Cell-free therapy is an alternative to cell-based therapy, which is based on the use of extracellular
vesicles (exosomes and microvesicles) derived from native or genetically/chemically modified cells.
The cell-free approach was developed in an attempt to circumvent the limitations of cell-based therapy.
Extracellular vesicles (EVs) retain properties of the donor cells, however, more importantly, they can
carry donor cell cargo or externally loaded content [10]. However, challenges remain in the use of EVs
for cancer therapy. EVs can have variable effects on tumor progression dependent upon their cargo;
heterogeneity of the isolated population and inconsistency of the EV cargo add an additional caveat to
their study and therapeutic use [11].
Genetic modification of cells using recombinant viruses can promote high levels of transgene
expression in a wide range of host cells [12]. With direct gene therapy, viral vectors, depending on
the type of virus and genome modification employed, can serve as immunomodulating agents [13] or
have direct oncosuppressive properties [14].
2. Recombinant Virus-Based Therapeutic Vaccines
Recombinant viruses can be used to genetically modify cells, triggering the expression of
tumor-specific antigens. These viruses can also be used to directly infect antigen-presenting cells
to boost anti-cancer immune responses [15]. The enhanced presentation of the tumor antigens to
immune cells leads to increased frequency and avidity of cytotoxic T-cells [16]. Additionally, transgenes
expressed by the viral vector are more immunogenic than antigens administered with adjuvants [17].
Therefore, recombinant viruses present a valuable tool for development of antitumor therapeutic
vaccines. The general mechanism of action of antitumor therapeutic vaccines is described in Figure 1A.
Tumor-specific antigens used for therapeutic vaccines should induce strong immune responses
and be expressed only in tumor cells. Target specificity can result from antigens generated by somatic
point mutations [18] or integrations of oncogenic virus genes [19] which are recognized by host T-cells.
Cancer-testis antigens (CTAs), for example MAGE-A1 [20], are considered ideal targets for cancer
vaccines due to their high immunogenicity and specific expression in germ and cancer cells [21,22].
Normal host antigens overexpressed by tumors may also be used as antigens for tumor immunotherapy.
Carcinoembryonic antigen (CEA) is a glycoprotein that is often overexpressed in colorectal and other
carcinomas, but also in some host cells. Its potential for therapeutic vaccination has been widely
investigated, however additional strategies are needed to overcome immune tolerance, for example
T-cell costimulation and blockage of CTLA-4 [23].
Several viruses have been used in attempts to develop optimal strategies for transgene delivery for
a range of cancers. These include, retroviruses, lentiviruses (including HIV-1) [24], adenoviruses [25],
adeno-associated viruses [26], poxviruses [27] and herpesviruses [28]. The choice of virus for a specific
cancer is determined by virus tropism, the size of the transgene that needs to be packaged, desired
longevity of transgene expression and potential safety concerns [29].
Poxviruses, which are able to induce both CD4+ and CD8+ mediated immune response against
heterologous antigens, are the most widely used viruses for anti-tumor vaccine production [30].
Poxviruses have a large genome (130–230 kb) that allows for the introduction of large foreign DNA
sequences. Several poxvirus vectors have been developed for gene therapy, including canary pox
virus-based ALVAC, modified vaccinia virus Ankara (MVA), and NYVAC [31–33].
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Figure 1. Recombinant virus based treatment of cancer. (A) ntitumor therapeutic vaccines, which are
b s d on viruses encoding tumor-specific antigens, boost anti-cancer immune responses by enhanced
presentation of the tumor antigens to immune cells. Another promisi g approach i the use of immune
cell-based vaccines to stimulate antitum r immunity. In his case, T-cells are genetically engineered
to express tumor-specific antigen receptors to improve recognition of cancer cells, for example CARs.
(B) Therapeutic viruses, for example MV-NIS (the Edmonston strain of measles virus), can also be
delivered to the tumor with mesenchymal stem cells (MSCs), which have a natural tropism toward
tumor niches. (C) Oncolytic viruses preferentially infect tumor cells and induce tumor cell death.
Additional genetic modification with immunomodulating genes such as granulocyte-macrophage
colony-stimulating factor (GM-CSF), can enhance anti-tumor effect. Oncolytic viruses also cause local
inflammation, which manifests as increased infiltration of immune cells into the tumor, local release of
interferons (IFNs), chemokines, danger-associated molecular patterns (DAMPs), pathogen-associated
molecular patterns (PAMPs) and mediate a tumor-specific immune response.
MVA has been used to generate a number of vaccines carrying specific antigens overexpressed in
tumor cells including 5T4 [34], mucin 1 (MUC1) [35] and prostate-specific antigen (PSA) [36]. Typically,
such vaccines have shown low toxicity in Phase I clinical trials and were highly immunogenic in some
patients [37,38]. However, despite the stimulation of an antigen-specific immune response, vaccination
did not lead to a significant clinical improvement in clinical trial participants. The lack of significant
improvement in patients can be explained by the ability of the tumors to evade the immune system
recognition [39]. Attempts to solve this problem have led to development of a number of viral vectors
which carry not only tumor-specific antigen but also sequences of immunomodulating proteins or
costimulatory molecules.
For example, TG4010 vaccine, which is an MVA encoding the MUC1 antigen as well as the human
interleukin 2 (IL-2) gene, was shown to be safe in Phase I clinical trials. The Phase II clinical trial showed
significant activation of MUC1 CD8+ specific immune response in more than half of the patients with
PSA [40]. However, in patients diagnosed with metastatic clear cell renal carcinoma, treatment with
MVA MUC1 vaccine combined with interferon α2a (IFN-α-2a) and IL-2 failed to establish long-term
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CD4+ and CD8+ immune responses [41] even though cytokine combination showed a statistically
significant superiority in terms of response in renal carcinoma patients [42].
TRICOM poxviral vaccine encoding CEA and three costimulatory molecules B7.1, inter-cellular
adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3 or CD58),
was used to treat patients with CEA-expressing cancers in combination with IFN-α-2b. Administration of
IFN-α-2b led to significant increase in overall survival (OS) compared to the vaccine alone [43]. Preclinical
investigations using a mouse model with CT26-MUC1 tumors showed that combination of the TG4010
vaccine with immune checkpoint inhibitors anti-programmed cell death 1 (anti-PD-1)/programmed cell
death ligand 1 (anti-PD-L1) resulted in delay of tumor onset as compared with TG4010 alone [44].
Multiple clinical trials have demonstrated the efficacy of combined therapy where various viral
vaccines were used together with chemotherapy or radiotherapy. For example, TG4010 vaccination
enhanced the effect of cisplatin and gemcitabine in a Phase IIB clinical trial in patients with non-small-cell
lung cancer [45]. However, in another clinical study, the combination of modified vaccinia Ankara-5T4
with cyclophosphamide (CY) did not increase vaccine-mediated immune responses [37]. Injection of
the TG4010 vaccine after a single 8 Gy radiation exposure increased the survival rate of RenCa-MUC1
cell-injected mice compared with vaccine, radiation, or radiation with MVA empty vector [46]. It appears
that combined therapy has great potential which require further investigation.
In addition to the ability of tumors to evade immune surveillance, the natural ability of the host’s
immune system to neutralize viral vaccines can limit the efficacy of viral vaccines, because booster
doses do not increase antigen-specific immune responses [47]. Another disadvantage of antigen-specific
vaccination using a single virus vector, is the likelihood that the immune response is mostly directed
against highly immunogenic viral antigens, rather than tumor-specific antigens, which are often weak
immunogens [48]. One approach to overcome this problem is to use two different recombinant viral
vaccines that carry the same tumor-specific antigen to enhance tumor-specific immune responses.
For example, the efficacy of multiple vaccinations (2–6 times) with MVA combined with simian
adenovirus ChAdOx1 encoding mouse STEAP1 antigen was shown to be effective in the treatment of
mice with prostate cancer. Vaccination with these viruses in combination with PD-1 blocking antibody
significantly improved animal survival rate, and tumors were not observed in 80% of mice [49].
The idea of stimulating the host anti-tumor immune response by injecting viruses encoding
tumor-specific antigens has been tested in large number of in vitro and in vivo studies, as well as
clinical trials. However, patients, participating in these clinical trials, were already at the advanced
stages of tumor development, when standard therapy was not effective. At these stages the immune
system becomes significantly suppressed by tumor [50], leading to failure of induction of an adequate
response to vaccination.
The large number of ongoing clinical trials (see Table 1) using viral vaccines combined with various
therapeutic agents suggests that researchers remain hopeful of identifying effective drugs capable
of significantly enhancing the immune response against tumors, despite the weakened immunity in
cancer patients.
Table 1. A number or registered clinical trials of virus-based or virus-engineered therapeutic agents
(according to clinicaltrials.gov).
Clinical Trial Phase
Therapeutic agent I, I/II II, II/III III IV N/A * Total
Oncolytic virus 73 31 7 0 4 115
Virus-based vaccine 39 38 0 0 0 77
Virus-engineered CAR T-cell 311 22 3 1 23 360
Other virus-engineered cell-based
vaccines (DCs, MSCs) 11 4 0 0 0 15
* N/A, Not Applicable.
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3. Virus-Based Engineering of Cell-Based Vaccines
The idea of using autologous ex vivo modified immune cells inspired new ideas in the field of
antitumor vaccines. This approach has proven more successful and, currently, FDA has approved
three immune cell-based vaccines to stimulate antitumor immunity. KYMRIAH (tisagenlecleucel)
and YESCARTA (axicabtagene ciloleucel) are patient’s T-cells genetically modified using lentiviral
or retroviral vectors, respectively, encoding anti-CD19 chimeric antigen receptor (CAR). YESCARTA
was FDA approved in October 2017 for relapsed-refractory lymphoma (NCT02348216). KYMRIAH
was approved for diffuse large B-cell lymphoma (DLBCL), TFL and high-grade B-cell lymphoma
treatment after at least two lines of therapy on 1 May 2018 (NCT02445248). The third antitumor
therapeutic vaccine PROVENGE (sipuleucel-T) was approved in 2010 for the treatment of prostate
cancer. This vaccine is not subjected to direct genetic modification, instead, autologous antigen
presenting cells (APCs) are cultivated in presence of recombinant human granulocyte-macrophage
colony-stimulating factor (GM-CSF) and prostatic acid phosphatase (PAP), an antigen expressed in
prostate cancer tissue [51]. All approved drugs for cancer therapy using recombinant viruses are
summarized in Table 2.
Table 2. FDA approved recombinant virus-based drugs.
Drug
IMLYGIC (Talimogene
Laherparepvec, T-Vec), Oncolytic
Virus
YESCARTA (Axicabtagene
Ciloleucel), Genetically
Modified Autologous T-cell
KYMRIAH (Tisagenlecleucel),
Genetically Modified Autologous
T-cell
Approval date 2015 2017 2018
Viral vector HSV-1 Retrovirus Lentivirus
Genetic
modification
Deletions in γ34.5 and α47 genes
and insertion of GM-CSF gene Insertion of anti-CD19 CAR Insertion of anti-CD19 CAR
Application In patients with melanomarecurrent after initial surgery
Diffuse large B-cell lymphoma
(DLBCL), TFL and high-grade
B-cell lymphoma
B-cell precursor acute lymphoblastic
leukemia (ALL), DLBCL, high grade
B-cell lymphoma
Mechanism of
action
Causes lysis of tumor, followed by
release of tumor-derived antigens,
which together with virally
derived GM-CSF may promote an
antitumor immune response
T-cell activation, proliferation,
acquisition of effector functions
and secretion of inflammatory
cytokines and chemokines. This
sequence of events leads to killing
of CD19-expressing cells
Identify and eliminate CD19-expressing
malignant and normal cells
Adverse
reactions
Fatigue, chills, pyrexia, nausea,
influenza-like illness,
and injection site pain
Cytokine release syndrome,
neurological toxicities, infections
and febrile neutropenia,
prolonged cytopenia,
hypogammaglobulinemia
Cytokine release syndrome,
neurological toxicities, infections and
febrile neutropenia, prolonged
cytopenia, hypogammaglobulinemia
Clinical studies
Randomized phase III trial
(NCT00769704). Patients with
stage IIIB–IV melanoma were
injected with T-Vec or GM-CSF. OS
in GM-CSF arm was 18.9 months,
and T-Vec arm was 23.3 months;
objective response in both arms
was 5.7% and 26.4% of patients
In Phase II clinical trial
(NCT02445248) efficacy was
established based on complete
remission (CR). Half of the
patients achieved CR, while 21%
achieved a partial response
ALL: In Phase II clinical trial
(NCT02228096), efficacy of KYMRIAH
was established based on complete
remission (CR) within 3 months after
infusion. Overall, 83% of patients
achieved CR.
DLBCL: In Phase II clinical trial
(NCT02445248), efficacy was
established based on complete response
(CR) and partial response (PR). Overall
50% of patients achieved CR or PR
The use of CAR T-cell approaches for immunotherapy is gaining momentum as evidenced by
the number of active clinical trials. Few clinical trials have used virus-engineered DC-based vaccines
to investigate the use of DCs, genetically modified to express various tumor-associated antigens,
to induce antigen-specific immune responses. For example, adenovirus carrying the P53 gene has been
used to produce a DC-vaccine to promote anti-p53-specific immunity (NCT00049218, NCT00776295).
Three active dose-escalation trials of MSCs are using viral infection to express TRAIL (NCT03298763),
IL-12 (NCT02530047) or IFN-β genes (NCT02079324). The number of clinical trials with viral vectors
for cell-based vaccine production is shown in Table 1.
Biomedicines 2018, 6, 94 6 of 14
4. Oncolytic Viruses
The genetic modification of viral genomes, which was the basis for the development of viral
vaccines, has become the framework for developing another approach for cancer therapy using
oncolytic viruses. Oncolytic viruses are able to preferentially infect tumor cells directly, in contrast
to viral vaccines, which are mainly used to modify the immune cells [17]. Most viruses can replicate
more actively in cancer cells, because anti-viral immune responses, for example interferon production
and apoptosis, are impaired in cancer cells [52]. To improve the specificity of viral oncolysis, viruses
that are non-virulent in humans or genetically modified viruses can be used [14]. Genetic modification
of viral genome also allows the introduction of genes to enhance immune response against tumor
cells [53,54]. Oncolytic viruses typically enter their target cells following binding to specific host-cell
surface receptors. For example, adenoviruses bind to coxsackie and adenovirus receptor, which is
expressed on the surface of a large number of tumor cells [55]. Oncolytic viruses based on herpes
simplex virus type 1 (HSV-1) successfully infect cells that carry on their surface herpesvirus entry
mediator (HVEM), nectin-1 and 3-O-sulfate-modified heparan sulfate receptors, while HSV-2-based
oncolytic viruses bind to HVEM, nectin-1 and nectin-2 receptors [56].
HSV-1-based viruses are the most commonly used viruses in oncolytic therapy. To date, there
are three generations of these viruses, among them second and third generations have the most
potent anti-cancer activity. The second-generation HSV-based virus G207 carries one mutation at
both loci of γ34.5 gene, encoding infected cell protein 34.5 (ICP34.5), which is necessary for HSV-1
infection of host cells. In addition, a disabling lacZ insertion in UL39 that encodes the large subunit
of viral ribonucleotide reductase (RR), inactivates RR. This increases virus specificity for tumor cells
(which have higher levels of endogenous RR, complementing viral RR deficiency) and thus enhances
virus safety for non-malignant cells and tissues [57]. T-Vec (Imlygic, talimogene laherparepvec) is
another second-generation virus, which was the first approved for clinical use. T-Vec comprises HSV-1
with deletions in γ34.5 and α47 genes (the latter encoding ICP47 protein), and human GM-CSF gene
insertion, which increases the immunogenicity of the virus [53]. The third-generation HSV-based
oncolytic virus G47∆ was obtained by introducing a third mutation into the HSV-1 G207 genome. In
addition to the mutations in the γ34.5 and α47 genes, there is an insertion of lacZ gene into the icp6
gene site leading to RR inactivation [58].
Vaccinia virus-based oncolytic virus JX-594 (Pexa-Vec, pexastimogene devacirepvec), in which
the thymidine kinase (tk) gene is replaced with human GM-CSF and β-galactosidase (β-gal) genes,
is also undergoing clinical trials [59]. To ensure selective replication in tumor cells and increase the
safety, the e1a gene is commonly deleted in oncolytic adenoviruses [60,61]. These oncolytic viruses are
discussed in more details in the review by Fukuhara et al. [14].
The ability of oncolytic viruses to induce tumor cell death was shown in vitro [62,63], in vivo [64]
and in clinical trials [61]. Based on the large volume of accumulated data, a significant number
of oncolytic viruses have reached the stage of clinical testing. In Phase I clinical trials, the safety of
a number of oncolytic viruses, for example, HSV-1-based TBI-1401 (HF10) (NCT02428036) and HSV1716
(NCT01721018), and the ability of the JX-594 virus to replicate in tumor cells were demonstrated [65].
Prolonged patient survival is also shown in a number of clinical trials. For example, the one- and
two-year median OS of patients with advanced head and neck cancer after treatment with oncolytic
vaccinia virus GL-ONC1 was 86% and 76%, respectively, which is significantly higher than the known
OS for conventional treatment (70% and 60%, respectively) (NCT01584284). An increase in median OS
after administration of a large dose of JX-594 also indicates the effectiveness of therapy with oncolytic
viruses (NCT00554372). A high success rate was achieved in clinical trials of T-Vec oncolytic virus.
In a randomized Phase III trial (NCT00769704), patients with unresectable stage IIIB-IV melanoma
were treated with T-Vec or subcutaneous human GM-CSF injection. The median OS in the human
GM-CSF arm was 18.9 months, while in the T-Vec arm it was 23.3 months. The overall response rate
in the arms was 5.7% and 26.4% of patients, respectively [66]. This data shows that T-Vac vaccine is
effective in a proportion of patients with unresectable stage IIIB–IV melanoma.
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In addition to the oncolytic effect, viruses cause local inflammation, which manifests with
increased infiltration of immune cells into the tumor [60], local release of IFNs, chemokines, danger-
associated molecular patterns (DAMPs) [67], pathogen-associated molecular patterns (PAMPs) and
mediates a tumor-specific immune response [68]. The generation of tumor-specific immune responses
by DAMPs and PAMPs has been comprehensively discussed elsewhere [69,70]. The lysis of cancer cells
also leads to the release of tumor-specific antigens that can induce a broader antitumor CD8+ T-cell
response. For example, administration of T-Vec to patients with metastatic melanoma increases the
number of melanoma associated antigens recognized by T-cells (MART-1) specific T-cells as compared
to controls [71]. A phase I study with ONCOS-102 oncolytic adenovirus showed induction of a systemic
tumor antigen-specific T-cell response in 9 out of 12 participants, despite the heterogeneity of the
patient population [60]. Interestingly, in a Phase II clinical trial, JX-594 oncolytic virus was able to infect
tumor-associated endothelial cells, as well as cancer cells, ultimately obliterating tumor vasculature
while leaving healthy vessels unaffected in patients with hepatocellular carcinoma (HCC) [72].
Oncolytic virus infection can trigger immune responses which suppress viral replication.
The immune system produces neutralizing antibodies [61] and mobilizes innate immune cells [68] to
restrict virus replication. If viruses are capable of inducing viremia, activation of an anti-viral immune
response significantly reduces the therapeutic efficacy of oncolytic viruses. MV-NIS, the Edmonston
strain of measles virus, which is genetically modified to express the human sodium-iodide symporter,
specifically targets cells expressing high levels of CD46 on the surface. In a Phase I trial, MV-NIS
was able to establish viremia, which led to production of neutralizing antibodies to MV-NIS in all
patients [73]. To mask the virus from immune detection and limit viral immunogenicity, a cell-mediated
viral delivery approach can be used. MSCs are promising cellular vectors because of their natural
tropism to tumor sites [8]. Thus, human bone marrow-derived MSCs, infected with measles virus,
migrated to orthotopically implanted HCC tumor cells and significantly suppressed tumor growth
in both antibody-naïve and passively-immunized severe combined immunodeficiency (SCID) mice.
In contrast, direct injection of virus had an anti-tumor effect only in antibody-naïve SCID mice [74].
The mechanism of MSC-based delivery of MV-NIS is shown in Figure 1B.
Most of the adverse effects associated with oncolytic vaccination are flu-like symptoms,
such as fever/chills, rigors, nausea or vomiting [66,75]. Anemia [61], neutropenia, leukopenia and
thrombocytopenia [73] are also reported, but only in some cases [61]. Unlike conventional drugs,
many oncolytic viruses do not reach maximum tolerated dose (MTD), or dose limiting toxicity
(DLT) [60,65,73]. Consequently, oncolytic virus-based treatment is commonly well tolerated.
Oncolytic virus-based therapy is also combined with chemotherapeutic drugs and human
monoclonal antibodies. Potentially, combination of various treatment strategies could improve
antitumor responses. For example, in a Phase Ib trial, T-Vec in combination with ipilimumab was
used for melanoma treatment. Objective response rate in the combination arm was 39%, while in
ipilimumab arm OR was 18% [76] (NCT01740297). The efficacy of T-Vec combination with Paclitaxel
(NCT02779855) and JX-594 with the immune checkpoint inhibitor Durvalumab (NCT03206073) are
also investigated in active clinical trials.
It is also worth mentioning oncolytic viruses which are not subjected to genetic modification.
For example, wild type reoviruses predominantly replicate in tumor cells without affecting normal
cells, targeting cells with an activated Ras pathway [77]. In a number of Phase II trials Reolysin
(pelareorep), a reovirus based vaccine, was used in combination with various chemotherapeutic drugs
(for example, gemcitabine, paxlitaxel, and cisplatin). Combined reovirus therapy has shown variable
effects, having either a slight increase in median OS [78], or a delayed effect on the OS [79]. Reolysin
showed a good therapeutic effect when combined with paclitaxel and carboplatin, in non-small cell
lung cancer. This combination increased the objective response rate from 20% to 31% [80]. Another
promising oncolytic virus is coxsackievirus A21 (CVA2, CAVATAK) which showed highly encouraging
overall immune related progression free survival rate of 39% at six months in patients with stage IIIc
Biomedicines 2018, 6, 94 8 of 14
and IV malignant melanoma (NCT01227551). The general mechanism of action of oncolytic viruses is
shown in Figure 1C.
Oncolytic virus-based therapy is considered to be a breakthrough in cancer treatment. Indeed,
direct lysis of tumor cells and induction of tumor-specific immunity may prolong patient survival
rate. Suitable genetic modifications and combination with various chemotherapeutic drugs can be
selected according to the type and stage of the cancer to achieve the most beneficial therapeutic effect.
Many clinical trials (see Table 1) using various types of oncolytic viruses present the evidence that
oncolytic viruses might be useful in combination therapy of malignancies.
5. Virus-Mediated Immunomodulation and Oncosuppression
In addition to cytotoxic effect and induction of tumor-specific immune response, recombinant
viruses can directly modify tumor cells and the tumor microenvironment. For example, Rossowska et al. [81]
used lentivirus (LV) encoding shRNA against TGF-β1 (shTGF-β1) to enhance the immunomodulatory
effect of an antigen-primed dendritic cell (DC)-based vaccine. LV was injected into mice with
murine colon carcinoma (MC38 cells) the day before the administration of the DC-based vaccine.
However, the combination of LV-shTGF-β1 with DC-vaccine did not produce a significant effect.
Cyclophosphamide used before the viral infection led to significant suppression of tumor growth
compared to combined use of CY with DC-vaccine or LV-shTGF-β1 [81]. Co-delivery of TGF-β
inhibitor SB-505124 and adenoviral vector carrying IL-12 gene in B16 melanoma xenograft mice
significantly delayed tumor growth and increased animal survival rate in vivo [82]. Lentiviral infection
of breast cancer MCF-7 cells with USP39 shRNA induced G0/G1-phase arrest and apoptosis in vitro;
the deubiquitinating enzyme USP39 plays important roles in mRNA processing [83].
Recombinant viruses can also be used to deliver tumor suppressor genes and apoptosis-inducing
genes. For instance, lentivirus carrying human soluble tumor necrosis factor-related apoptosis-inducing
ligand (sTRAIL) gene induced apoptosis in SGC-7901 cells in vitro by secreting bioactive sTRAIL
protein [84]. In turn, recombinant adeno-associated virus (AAV)-encoding sTRAIL showed its safety
in mice and in cynomolgus monkeys [85]. Interestingly, long-term expression of sTRAIL led to
suppression of tumor growth in a mouse model with human SMMC-7721 liver cancer cells [86].
Combined therapy using adenovirus encoding phosphatase and tensin homolog (PTEN) gene, which is
an oncosuppressor, and LY294002, the selective phosphatidylinositol 3-kinase (PI3K) inhibitor, led to
significant induction of apoptosis in U251 glioma cells in vitro and in U251 subcutaneous glioblastoma
xenograft model in vivo [87]. Adenoviral vector encoding REIC/Dkk-3 gene suppressed the cell growth
of human prostate adenocarcinoma LNCaP cells in vitro by inhibiting CD147 expression [88]. Thus,
virus-mediated immunomodulation and oncosuppression can be used, either alone, or in combination
with other therapeutic agents to increase its effectiveness.
6. Conclusions
Cancer therapy using recombinant viruses shows great promise and is currently being
extensively investigated. The most studied approach includes using viral vectors as vaccines carrying
tumor-specific antigens. These vaccines are aimed at stimulating the host’s immune system to
suppress tumors and enhance T-cell-specific immune responses. Combination of these vaccines with
immunomodulating agents is important to achieve the highest antitumor effect. It appears that the
search for a successful combination of tumor antigen-bearing vaccines and other therapeutic agents
will be the key to successful cancer treatment in a greater number of patients and cancer types.
Another breakthrough in virus-mediated cancer therapy is the use of oncolytic viruses, which have
a direct cytotoxic effect on tumor cells, and additionally stimulate the immune response by releasing
tumor-specific antigens and inducing local inflammation. Genetic modification of oncolytic viruses
allows improvements in their specificity and immunogenicity to increase the effectiveness of therapy.
As in the case of viral vaccines, combination with other therapeutic agents allows researchers to find
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the most effective approach for cancer treatment. This includes an FDA-approved oncolytic virus
T-Vec which is successfully used to treat patients with melanoma.
In view of the fact that cancers are complex diseases that can arise as a result of various mutations,
the approaches for the treatment of different cancers will vary. Most likely, the combination of various
methods of treatment, including virus-mediated therapy, will lead to the most promising results in the
fight against cancer.
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